AMLo Biosciences

The AMLo team has enjoyed a productive and interesting meeting at the 2025 combined EADO and World Congress on Melanoma #MelanomaEADO2025 meeting in Athens, Greece. Our combined approach of academic presentation and commercial presence optimises our impact. Key takeaways from this meeting include: 💡Change in focus for clinicians to reduce unnecessary investigations for low-risk early-stage melanoma patients 👉 Credible biomarkers are essential to risk stratify these low-risk melanomas 👩🔬 Overtreatment of Stage IIs is a concern, especially amongst the IIBs 🌟 Addition of clinical pathological features to complement genetic and IHC tests was seen as essential to achieve optimal personalised risk stratification during plenary sessions and debates ✨ AMBLor has relevance to all these important points. It was pointed out in a main plenary session that AMBLor has superiority over all other proprietary biomarkers for identifying low risk early-stage melanomas. 📒 AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor® test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor® has received its UKCA mark in the UK. Marie Labus Penny Lovat Dean Slagel Sean Davis Alex Buchan Andrew Edmonds Alexander Shadbolt David Macdonald Alexander Pogorzelski

Advances in #melanoma treatment have significantly improved outcomes, yet melanoma remains an aggressive cancer requiring vigilant management to ensure continuity of care. https://bit.ly/4kTGD9w Patient satisfaction and involvement in decision-making are increasingly recognised as critical components of care, ensuring management aligns with individual needs. AMLo Biosciences recognise that accurate prognostic information plays a vital role in ensuring continuity of care. Our #AMBLor® biomarker test that accurately identifies early-stage melanomas at low risk of progression, provides additional risk information at diagnosis that can reduce unnecessary interventions, tailor follow-up schedules and improve patient-centred care. AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor® test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor® has received its UKCA mark in the UK. #dermatology #dermatopathology #skincaner #histopathology #oncology #cancerresearch #biomarkers #HealthcareInnovation

We are delighted to have a published abstract and a talk on our early research at the World Congress of Melanoma & EADO Congress, 3-5 April, Athens, Greece. This work, currently at research stage and with more work in progress, looks at the combined use of #AMBLor® with a machine learning algorithm of clinical and pathological features to identify patient subsets at high risk of disease recurrence. Abstract A-407: Harnessing machine learning to the immunohistochemical expression of AMBRA1 and Loricrin to identify non-ulcerated AJCC Stage I/II melanomas at high-risk of metastasis. Free Communication O403: Friday 4 April, 16:50 Prof Penny Lovat, Newcastle upon Tyne, UK AMLo Biosciences will also be exhibiting at stand #24 so stop by and find out more about our prognostic biomarker test AMBLor® that can accurately identify early-stage melanomas at low risk of disease progression. Melanoma World Society - MWS European Association of Dermato-Oncology AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor® test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor® has received its UKCA mark in the UK. #melanoma #dermatology #dermatopathology #skincaner #histopathology #oncology #cancerresearch #biomarkers #HealthcareInnovation

Katherine Ryan's recent second #melamona diagnosis is a stark reminder of the aggressive nature of this #skincancer type. Awareness is vital. https://bit.ly/4bYSwXR We extend our sympathy to Katherine during this challenging time and support her move to socialise this to raise awareness of being #skinaware. Understanding and monitoring skin changes is critical and anything unusual needs to be checked by a healthcare professional. #AMBLor®, our validated biomarker prognostic is available for clinicians to use. It personalises care by stratifying early-stage melanoma for low-risk of metastasis. This information can help clinical management of melanoma, potentially offering patients peace of mind about progression, providing the opportunity to remove the need for further invasive diagnostic procedures, thus enabling a personalised follow-up schedule based on the patient’s risk profile. AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor® test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor® has received its UKCA mark in the UK. #dermatology #dermatopathology #skincaner #histopathology #oncology #cancerresearch #biomarkers #HealthcareInnovation

AMLo Biosciences are excited to be attending 11th World Congress of Melanoma & 21st EADO Congress - find us at Stand #24 and find out more about our prognostic biomarker, #AMBLor®. Melanoma World Society - MWS European Association of Dermato-Oncology This year there is a packed programme, opening with a symposium on “Prognostic and predictive biomarkers in #melanoma”. This is followed later in the day by a session on the “Problem of over diagnosis in melanoma”, which we are interested to hear more about. In addition, Professor Alexander Eggermont, from the University Medical Centre, Utrecht, is the Keynote Speaker on Friday 5 April and will be tackling the topic “New diagnostics, prognostic biomarkers and systemic therapy strategies sharply reduce the need for surgery in melanoma”. AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor has received its UKCA mark in the UK. #dermatology #dermatopathology #skincaner #histopathology #oncology #cancerresearch #biomarkers #HealthcareInnovation

AMLo Biosciences want to share this great animation of how a #melanoma develops and spreads. It clearly shows the process of melanocyte changes as the start of #skincancer and what metastasis looks like. The message here is to avoid UV damage to the skin and to check moles regularly. See a dermatologist with any concerns. Stay #skinaware.

The countdown to the 11th World Congress of Melanoma & 21st EADO Congress has begun, and we are really looking forward to connecting with #melanoma experts from across the world. Melanoma World Society - MWS EADO - European Association of Dermato-Oncology Come and speak to the team at stand #24 and find out about our biomarker test #AMBLor® that accurately identifies early-stage melanomas at low risk of disease progression. www.amlo-biosciences.com AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor has received its UKCA mark in the UK. #dermatology #dermatopathology #skincaner #histopathology #oncology #cancerresearch #biomarkers #HealthcareInnovation

AMLo Biosciences would like to thank everyone who visited us at #AAD25 last week - it was great to see customers and discuss #AMBLor® as well as our MiS research pipeline in #melanoma. “Patient-tailored care” is the phrase that resonates with our customers. Showcasing the value of AMBLor®, our accurate biomarker prognostic, demonstrates a paradigm shift in melanoma care from population-based medicine to personalised medicine. AMBLor® reliably stratifies early-stage melanomas at low-risk of progression, even on thinner depth lesions that can’t be sent for any other prognostic testing. The test is quick, cost-effective and is supported by a dedicated team. Our case studies were of significant interest at AAD – with delegates better understanding the clinical value described by known healthcare providers. We are delighted that AMBLor® can provide extra prognostic information that helps inform clinical next steps and discussions around ongoing management, ultimately bringing us closer to individualised patient care. Please follow up with us if you have additional questions and look out for us at other meetings and conferences. Our next event is #EADO25 3-5 April, Athens. https://bit.ly/4bV1NQp AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor has received its UKCA mark in the UK. #dermatology #dermatopathology #skincancer #histopathology #oncology #cancerresearch

Jane Meaney, our CMO, is speaking at the inaugural Women in DiagnostiXX meeting on 18 March, at the British In Vitro Diagnostics Association (BIVDA) offices in London. Women in DiagnostiXX is a network for women, supporters and allies working in the health and medical diagnostics space. The event will feature a number of expert-led discussions and panel debates on career success in health technology. Jane is part of a panel discussion exploring the different routes into the diagnostics industry, challenges often faced by women in this field and advice on how best to overcome these barriers. She will be talking about her own experience at AMLo Biosciences, the all-female-led diagnostic company bringing innovative prognostics to patients and advancing #melanoma management. Find out more about our technology: www.amlo-biosciences.com Lucy L.

We are delighted to reshare this post from British Skin Foundation that highlights our work in #melanoma prognostics. Without BSF support we would not be where we are today. Overcoming many challenges, our initial research into biomarkers AMBRA1 and loricrin has resulted in #AMBLor® - our validated prognostic laboratory test available for clinicians to use. AMBLor® identifies early-stage melanomas at low-risk of metastases. This information, additional to diagnostic staging data, can help shape clinical management of melanoma, offering patients peace of mind about progression, potentially removing the need for further invasive diagnostic procedures and enabling a more personalised follow-up schedule. AMBLor® testing service is provided by Avero Diagnostics as a physician-ordered, laboratory-developed test (LDT). The AMBLor® test meets the U.S. Food and Drug Administration (FDA) definition and requirements for LDTs, but it has not been reviewed by the FDA. AMBLor® has received its UKCA mark in the UK. #dermatology #dermatopathology #skincaner #histopathology #oncology #cancerresearch #biomarkers #HealthcareInnovation